Nickan Research Institute Journal of Renal Endocrinology 2423-6438 12 1 2026 01 01 Sodium-glucose cotransporter 2 inhibitors; revolutionizing diabetic kidney disease management e25204 e25204 EN Afagh Hassanzadeh Rad https://orcid.org/0000-0001-6980-8866 Gelayol Chatrnour https://orcid.org/0000-0001-5074-6415 Journal Article 2025 10 04 2026 03 20 Diabetic kidney disease (DKD), a leading cause of kidney failure, is driven by hyperglycemia and inflammation. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, initially for type 2 diabetes, transform DKD treatment by reducing glucose reabsorption, easing glomerular pressure, and shortening inflammation. These drugs are safe, with minor risks. Combining with GLP-1 agonists or mineralocorticoid antagonists may boost benefits. In addition, SGLT2 inhibitors slow DKD progression, enhancing patient outcomes. Future studies should refine combination therapies and personalized care.